BTIG Starts Coverage on Tiziana With Buy Rating as Key MS Trial Nears
Nasal foralumab aims to cut brain inflammation in SPMS and MSA ahead of October INFORM-MS data.
Already have an account? Sign in.
Nasal foralumab aims to cut brain inflammation in SPMS and MSA ahead of October INFORM-MS data.
Be the first to know when deals break, stocks move, or biotech headlines hit.